Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

  • STATUS
    Recruiting
  • days left to enroll
    59
  • participants needed
    320
  • sponsor
    Saint Luke's Health System
Updated on 13 May 2021
Investigator
Sheryl Windsor
Primary Contact
Chicago Medical Research (0.4 mi away) Contact
+25 other location

Summary

The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.

Description

A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and BNP), symptoms, health status, and quality of life in patients with chronic heart failure with preserved systolic function. An imaging substudy will also be conducted to explore the effects of dapagliflozin vs. placebo on various echocardiographic parameters.

Details
Condition Chronic Heart Failure With Preserved Systolic Function
Treatment Dapagliflozin matching placebo, Dapagliflozin 10Mg Oral Tablet
Clinical Study IdentifierNCT03030235
SponsorSaint Luke's Health System
Last Modified on13 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Symptoms of dyspnea (NYHA class II-IV) without evidence of a non-cardiac or ischemic explanation for dyspnea
Ejection fraction (EF) 45% as determined on imaging study within 24 months of enrolment with no change in clinical status suggesting potential for deterioration in systolic function
Elevated NT-proBNP ( 225 pg/ml) or BNP ( 75 pg/ml). For patients with permanent atrial fibrillation inclusion thresholds will be BNP 100 pg/mL or NTproBNP 375 pg/mL
Stable medical therapy for heart failure for 15 days as defined by: i. No addition or removal of ACE, angiotensin receptor blockers (ARBs), valsartan/sacubitril, beta-blockers, calcium channel blockers (CCBs) or aldosterone antagonists; ii.No substantial change in dosage (100% or greater increase or decrease from baseline dose) of ACE, ARBs, beta-blockers, CCBs or aldosterone antagonists
On a diuretic 15 days prior to screening visit and a stable diuretic therapy for 7 days
At least one of the following: i. Hospitalization for decompensated HF in the last 12 months; ii. Acute treatment for HF with intravenous loop diuretic or hemofiltration in the last 12 months; iii. Mean pulmonary capillary wedge pressure 15 mmHg or LV end diastolic pressure (LVEDP) 15 mmHg documented during catheterization at rest, or pulmonary capillary wedge pressure or LVEDP 25 mmHg documented during catheterization with exercise; iv. Structural heart disease evidenced by at least one of the following echo findings (any local measurement made within the 24 months prior to screening visit): a) left atrial (LA) enlargement defined by at least one of the following: LA width 3.8cm or LA length 5.0 cm or LA area 20 cm2 or LA volume 55 mL or LA volume index 29 mL/m2 b) or left ventricular hypertrophy (LVH) defined by septal thickness or posterior wall thickness 1.1 cm

Exclusion Criteria

Decompensated heart failure (hospitalization for heart failure within 7 days prior to screening)
History of type 1 diabetes
History of diabetic ketoacidosis
Estimated glomerular filtration rate (eGFR) < 20 at the screening visit by modified MDRD equation GFR (mL/min/1.73 m2 ) = 175 x (Scr) -1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African American)
Admission for an acute coronary syndrome (ST-elevation MI, non-ST-elevation MI, or unstable angina), percutaneous coronary intervention, or cardiac surgery within 30 days prior to the screening visit
Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the screening visit
Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy, or transcatheter aortic valve replacement) or CRT within the 90 days after the screening visit
Participation in any interventional clinical trial (with an investigational drug or device) that is not an observational registry within 15 days of the screening visit
History of hypersensitivity to dapagliflozin
For women of child-bearing potential: Current or planned pregnancy or currently lactating
Life expectancy <1 year at the screening visit
Patients who are volume depleted based upon physical examination at the time of the screening or randomization visit
BNP <75 pg/mL and NTproBNP<225 pg/mL at the screening visit. For patients with permanent atrial fibrillation exclusion thresholds will be BNP<100 pg/mL and NTproBNP<375pg/mL
Patients currently being treated with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin, ertugliflozin) or having received treatment with any SGLT-2 inhibitor within the 12 weeks prior to the screening visit
Average supine systolic BP <100 mmHg at the screening or randomization visit
Current history of bladder cancer
Donation of blood or bone marrow 12 weeks prior to the screening visit and no planned donations during the study period
Heart failure due to restrictive/infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe stenotic valve disease, and HOCM (hypertrophic obstructive cardiomyopathy)
Heart failure due to severe aortic or mitral regurgitation
Severe COPD thought to be a primary contributor to dyspnea
Isolated right heart failure due to pulmonary disease
Active and significant ischemia thought to be a primary contributor to dyspnea
Documentation of previous EF < 45%, under stable conditions, within the past 36 months
Complex congenital heart disease
Uncontrolled hypertension, defined as systolic blood pressure 200 mmHg during the screening visit (average value of three blood pressure measurements obtained in supine position)
Any other condition that in the judgment of the investigator would jeopardize the patient's participation in the study or that may interfere with the interpretation of study data or if the patient is considered unlikely to comply with study procedures, restrictions and requirements
Bariatric surgery within the past 6 months or planned bariatric surgery within the study time course
CardioMems device implantation within previous 4 weeks or planned CardioMems implantation during study period
For echo substudy only: patients with ventricular paced rhythm or left bundle branch block on the most recent clinically available 12-lead electrocardiogram
For echo substudy only: permanent atrial fibrillation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note